Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver M Bautista

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Contemporary Clinical Trials|February 4, 2017
Letter to the Editor in response to "N Folschweiller, V Berlaimont, SR Skinner, CM Wheeler, N Karkada, F Struyf, M Ryser. Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemp. Clin. Trials (2016), doi: 10.1016/j.cct.2016.12.022"Oliver M Bautista, Alain Luxembourg
Contemporary Clinical Trials|January 23, 2016
Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trialsOliver M Bautista, Alain Luxembourg
Journal of the National Cancer Institute|December 1, 2010
Re: Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infectionOliver M Bautista, Alfred Saah, Nubia Muñoz
Statistics in Medicine|October 21, 2003
Group sequential large sample T2-like chi2 tests for multivariate observationsJohn M Lachin, Samuel W Greenhouse, Oliver M Bautista
Biostatistics (Oxford, England)|April 7, 2006
Parametric survival models for interval-censored data with time-dependent covariatesYvonne H Sparling, Naji Younes, John M Lachin, et al.
Vaccine|January 1, 2008
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccinesCosette M Wheeler, Oliver M Bautista, Joanne E Tomassini, et al.
American Journal of Obstetrics and Gynecology|March 4, 2008
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American womenEliav Barr, Christine K Gause, Oliver M Bautista, et al.
Contemporary Clinical Trials|October 22, 2021
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in menAnna R Giuliano, Timothy Wilkin, Oliver M Bautista, et al.
Obstetrics and Gynecology|January 6, 2006
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trialConstance Mao, Laura A Koutsky, Kevin A Ault, et al.
Controlled Clinical Trials|April 12, 2003
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trialOliver M Bautista, John W Kusek, Leroy M Nyberg, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Contemporary Clinical Trials|February 4, 2017
Letter to the Editor in response to "N Folschweiller, V Berlaimont, SR Skinner, CM Wheeler, N Karkada, F Struyf, M Ryser. Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemp. Clin. Trials (2016), doi: 10.1016/j.cct.2016.12.022"Oliver M Bautista, Alain Luxembourg
Contemporary Clinical Trials|January 23, 2016
Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trialsOliver M Bautista, Alain Luxembourg
Journal of the National Cancer Institute|December 1, 2010
Re: Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infectionOliver M Bautista, Alfred Saah, Nubia Muñoz
Statistics in Medicine|October 21, 2003
Group sequential large sample T2-like chi2 tests for multivariate observationsJohn M Lachin, Samuel W Greenhouse, Oliver M Bautista
Biostatistics (Oxford, England)|April 7, 2006
Parametric survival models for interval-censored data with time-dependent covariatesYvonne H Sparling, Naji Younes, John M Lachin, et al.
Vaccine|January 1, 2008
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccinesCosette M Wheeler, Oliver M Bautista, Joanne E Tomassini, et al.
American Journal of Obstetrics and Gynecology|March 4, 2008
Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American womenEliav Barr, Christine K Gause, Oliver M Bautista, et al.
Contemporary Clinical Trials|October 22, 2021
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in menAnna R Giuliano, Timothy Wilkin, Oliver M Bautista, et al.
Obstetrics and Gynecology|January 6, 2006
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trialConstance Mao, Laura A Koutsky, Kevin A Ault, et al.
Controlled Clinical Trials|April 12, 2003
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trialOliver M Bautista, John W Kusek, Leroy M Nyberg, et al.
Pageof 2